U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H8N4.ClH
Molecular Weight 196.6371
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYDRALAZINE HYDROCHLORIDE

SMILES

c1ccc2c(c1)cn[nH]c2=NN.Cl

InChI

InChIKey=ZUXNZUWOTSUBMN-UHFFFAOYSA-N
InChI=1S/C8H8N4.ClH/c9-11-8-7-4-2-1-3-6(7)5-10-12-8;/h1-5H,9H2,(H,11,12);1H

HIDE SMILES / InChI

Molecular Formula C8H8N4
Molecular Weight 160.1762
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/cdi/hydralazine.html

Hydralazine is a direct-acting vasodilator that is used as an antihypertensive agent. Hydralazine works by relaxing blood vessels (arterioles more than venules) and increasing the supply of blood and oxygen to the heart while reducing its workload. It also functions as an antioxidant. It inhibits membrane-bound enzymes that form reactive oxygen species, such as superoxides. Excessive superoxide counteracts NO-induced vasodilation. Hydralazine is used for the treatment of essential hypertension, alone or as an adjunct. Also for the management of severe hypertension when the drug cannot be given orally or when blood pressure must be lowered immediately, congestive heart failure (in combination with cardiac glycosides and diuretics and/or with isosorbide dinitrate), and hypertension secondary to pre-eclampsia/eclampsia.

CNS Activity

Curator's Comment:: some metabolites of hydralazine are known to cross the blood-brain barrier

Originator

Curator's Comment:: In 1951 the Hypertension Division at Washington University initiated the use of hydralazine

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
400.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Hydralazine Hydrochloride

Approved Use

Severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure.

Launch Date

4.78137614E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3 μM
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered: HYDRALAZINE
HYDRALAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
407 μM × h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered: HYDRALAZINE
HYDRALAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered: HYDRALAZINE
HYDRALAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
13%
HYDRALAZINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Co-administed with::
ethanol
Sources:
unhealthy, 27
n = 1
Health Status: unhealthy
Condition: Hypertension
Age Group: 27
Sex: F
Population Size: 1
Sources:
Disc. AE: Tachycardia...
AEs leading to
discontinuation/dose reduction:
Tachycardia
Sources:
750 mg single, oral
Overdose
Dose: 750 mg
Route: oral
Route: single
Dose: 750 mg
Co-administed with::
clonazepam, p.o(10 mg, single)
Sources: Page: p.53, 54
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Hypertension
Age Group: 38
Sex: F
Population Size: 1
Sources: Page: p.53, 54
Disc. AE: Lethargy, Hypotension...
AEs leading to
discontinuation/dose reduction:
Lethargy
Hypotension
Tachycardia
Chest pain
Sources: Page: p.53, 54
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Disc. AE: Skin rash, Febrile reaction...
AEs leading to
discontinuation/dose reduction:
Skin rash (rare)
Febrile reaction (rare)
Sources:
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.2
Disc. AE: Systemic lupus erythematosus synd, Glomerulonephritis...
AEs leading to
discontinuation/dose reduction:
Systemic lupus erythematosus synd
Glomerulonephritis
Sources: Page: p.2
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.3
Disc. AE: Angina pectoris, Myocardial infarction...
AEs leading to
discontinuation/dose reduction:
Angina pectoris
Myocardial infarction
Peripheral neuritis
Sources: Page: p.3
40 mg single, intravenous
Recommended
Dose: 40 mg
Route: intravenous
Route: single
Dose: 40 mg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.1
Disc. AE: Systemic lupus erythematosus synd, Glomerulonephritis...
AEs leading to
discontinuation/dose reduction:
Systemic lupus erythematosus synd
Glomerulonephritis
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Tachycardia Disc. AE
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Co-administed with::
ethanol
Sources:
unhealthy, 27
n = 1
Health Status: unhealthy
Condition: Hypertension
Age Group: 27
Sex: F
Population Size: 1
Sources:
Chest pain Disc. AE
750 mg single, oral
Overdose
Dose: 750 mg
Route: oral
Route: single
Dose: 750 mg
Co-administed with::
clonazepam, p.o(10 mg, single)
Sources: Page: p.53, 54
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Hypertension
Age Group: 38
Sex: F
Population Size: 1
Sources: Page: p.53, 54
Hypotension Disc. AE
750 mg single, oral
Overdose
Dose: 750 mg
Route: oral
Route: single
Dose: 750 mg
Co-administed with::
clonazepam, p.o(10 mg, single)
Sources: Page: p.53, 54
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Hypertension
Age Group: 38
Sex: F
Population Size: 1
Sources: Page: p.53, 54
Lethargy Disc. AE
750 mg single, oral
Overdose
Dose: 750 mg
Route: oral
Route: single
Dose: 750 mg
Co-administed with::
clonazepam, p.o(10 mg, single)
Sources: Page: p.53, 54
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Hypertension
Age Group: 38
Sex: F
Population Size: 1
Sources: Page: p.53, 54
Tachycardia Disc. AE
750 mg single, oral
Overdose
Dose: 750 mg
Route: oral
Route: single
Dose: 750 mg
Co-administed with::
clonazepam, p.o(10 mg, single)
Sources: Page: p.53, 54
unhealthy, 38
n = 1
Health Status: unhealthy
Condition: Hypertension
Age Group: 38
Sex: F
Population Size: 1
Sources: Page: p.53, 54
Febrile reaction rare
Disc. AE
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Skin rash rare
Disc. AE
200 mg 1 times / day multiple, oral (max)
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Glomerulonephritis Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.2
Systemic lupus erythematosus synd Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.2
Angina pectoris Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.3
Myocardial infarction Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.3
Peripheral neuritis Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.3
Glomerulonephritis Disc. AE
40 mg single, intravenous
Recommended
Dose: 40 mg
Route: intravenous
Route: single
Dose: 40 mg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.1
Systemic lupus erythematosus synd Disc. AE
40 mg single, intravenous
Recommended
Dose: 40 mg
Route: intravenous
Route: single
Dose: 40 mg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.1
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >1000 uM]
no
unlikely
unlikely
unlikely
unlikely
yes [IC50 197 uM]
yes [Ki 83 uM]
yes
yes
yes
yes
yes
yes
Tox targets
PubMed

PubMed

TitleDatePubMed
Clinical consequences of polymorphic acetylation of basic drugs.
1977 Sep
Immunological side-effects of antihypertensive drugs.
1979
Effects of chronic treatment with captopril (SQ 14,225), an orally active inhibitor of angiotensin I-converting enzyme, in spontaneously hypertensive rats.
1979 Apr
Acute hemodynamic effects of pinacidil and hydralazine in essential hypertension.
1985 Mar
Therapeutic implications of hypertension-induced glomerular injury. Comparison of enalapril and a combination of hydralazine, reserpine, and hydrochlorothiazide in an experimental model.
1985 Sep 27
Suppression of ventricular arrhythmias after coronary artery ligation by pinacidil, a vasodilator drug.
1985 Sep-Oct
Drug-associated glomerulopathies.
1986
Comparative study of endralazine and hydralazine for the treatment of hypertension uncontrolled by a beta-blocker and diuretic.
1986
Clinical pharmacology and therapeutic role of prazosin and related alpha-adrenoceptor antagonists.
1986
Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat.
1986 Jun
Inhibition of sympathoadrenal activity by atrial natriuretic factor in dogs.
1987 Apr
Isolated minimal change nephropathy associated with diclofenac.
1987 Jul 18
Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans.
1987 May
Hydralazine-induced cholestatic jaundice following liver transplantation.
1989 Jan
Myocardial ischemia during isoflurane anesthesia: the effect of substituting halothane.
1989 Jun
Prevention of arterial disease in experimental renal hypertension.
1990 Apr
Changes of atrial natriuretic peptide and its messenger RNA with development and regression of cardiac hypertrophy in renovascular hypertensive rats.
1990 Jan
Acute cocaine toxicity: antagonism by agents interacting with adrenoceptors.
1990 Jun
Hemodynamic effects of adenosine agonists in the conscious spontaneously hypertensive rat.
1990 Sep
Features of the acute hypotensive action of carvedilol and its ameliorating effect on myocardial ischemia.
1991
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.
1991 Aug 1
Cardiotoxicity of hydralazine and minoxidil in the rat. Influence of age.
1991 Feb
Role of connective tissue growth factor in vascular and renal damage associated with hypertension in rats. Interactions with angiotensin II.
2006 Dec
AT1 receptor blockade is superior to conventional triple therapy in protecting against end-organ damage in Cyp1a1-Ren-2 transgenic rats with inducible hypertension.
2006 Dec
A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.
2006 Dec 20
Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid.
2006 Dec 27
Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial.
2007 Apr 3
A randomised comparison of hydralazine and mini-bolus diazoxide for hypertensive emergencies in pregnancy: the PIVOT trial.
2007 Aug
Persistent hypertension and progressive renal injury induced by salt overload after short term nitric oxide inhibition.
2007 Dec
The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study.
2007 Feb 26
Interactions between aldosterone and connective tissue growth factor in vascular and renal damage in spontaneously hypertensive rats.
2007 Mar
D-Penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson disease.
2007 Nov
Beneficial effects of the Rho kinase inhibitor Y27632 in murine puromycin aminonucleoside nephrosis.
2008
Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition.
2008 Dec
The prince and the pauper. A tale of anticancer targeted agents.
2008 Oct 23
Simultaneous posterior ischemic optic neuropathy, cerebral border zone infarction, and spinal cord infarction after correction of malignant hypertension.
2008 Sep
Administration of angiotensin II, but not catecholamines, induces accumulation of lipids in the rat heart.
2009 Feb 14
"Pulse" treatment with high-dose angiotensin blocker reverses renal arteriolar hypertrophy and regresses hypertension.
2009 Jan
4-Hydrazino-2-(methyl-sulfan-yl)-pyrimidine.
2009 Jan 31
Resveratrol attenuates angiotensin II-induced interleukin-6 expression and perivascular fibrosis.
2009 Jun
D-penicillamine-induced autoimmunity: relationship to macrophage activation.
2009 Sep
Hydralazine for essential hypertension.
2010 Aug 4
Chitosan nanoparticle-based neuronal membrane sealing and neuroprotection following acrolein-induced cell injury.
2010 Jan 29
HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats.
2010 Sep
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Antiatherogenic effect of bisvanillyl-hydralazone, a new hydralazine derivative with antioxidant, carbonyl scavenger, and antiapoptotic properties.
2011 Jun
Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway.
2011 May
Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.
2012 May
Diesel exhaust induced pulmonary and cardiovascular impairment: the role of hypertension intervention.
2013 Apr 15
Acrolein and chloroacetaldehyde: an examination of the cell and cell-free biomarkers of toxicity.
2013 Feb 25
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: can also be used intramuscularly or as a rapid intravenous bolus injection directly into the vein. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/040136s005lbl.pdf
Initial dose: 10 mg orally 4 times a day for the first 2 to 4 days. Increase to 25 mg orally 4 times a day for the balance of the first week. For the second and subsequent weeks, increase dosage to 50 mg orally 4 times a day.
Route of Administration: Oral
In Vitro Use Guide
Hydralazine (0.03-10 mmol.L(-1)) inhibited the activities of both PKA and PKG with IC50 of 1.2 and 2.5 mmol.L(-1), respectively
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:00:13 UTC 2021
Edited
by admin
on Fri Jun 25 21:00:13 UTC 2021
Record UNII
FD171B778Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HYDRALAZINE HYDROCHLORIDE
EP   HSDB   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
Common Name English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE
Common Name English
HYDRALAZINE HYDROCHLORIDE [USP-RS]
Common Name English
HYDRALAZINE HYDROCHLORIDE [WHO-IP]
Common Name English
APRESOLINE-ESIDRIX COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
SER-A-GEN COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
DRALZINE
Brand Name English
UNIPRES COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF APRESAZIDE
Common Name English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF SERPASIL-APRESOLINE
Common Name English
HYDROSERPINE PLUS (R-H-H) COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
SER-AP-ES COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF UNIPRES
Common Name English
PHTHALAZINE, 1-HYDRAZINO-, MONOHYDROCHLORIDE
Common Name English
APRESSINUM [WHO-IP]
Common Name English
MC-1101
Code English
HYDRALAZINI HYDROCHLORIDUM [WHO-IP LATIN]
Common Name English
APRESAZIDE COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
HYDRA-ZIDE COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
HYDRAP-ES COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF SER-A-GEN
Common Name English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF HYDROSERPINE PLUS (R-H-H)
Common Name English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF CAM-AP-ES
Common Name English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF HYDRA-ZIDE
Common Name English
HYDRALAZINE HYDROCHLORIDE [MART.]
Common Name English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF HYDRAP-ES
Common Name English
DRALSERP COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
HYDRALAZINE HCL
Common Name English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF DRALSERP
Common Name English
HYDRALAZINE HYDROCHLORIDE [HSDB]
Common Name English
SERPASIL-APRESOLINE COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
HYDRALAZINE HYDROCHLORIDE [USP]
Common Name English
CAM-AP-ES COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
HYDRALAZINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
1-HYDRAZINOPHTHALAZINE MONOHYDROCHLORIDE
Systematic Name English
HYDRALAZINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF SER-AP-ES
Common Name English
HYDRALAZINE HYDROCHLORIDE [MI]
Common Name English
APRESOLINE
Brand Name English
HYDRALAZINE HYDROCHLORIDE [VANDF]
Common Name English
HYDRALAZINE HYDROCHLORIDE [WHO-DD]
Common Name English
BIDIL COMPONENT HYDRALAZINE HYDROCHLORIDE
Common Name English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF APRESOLINE-ESIDRIX
Common Name English
NSC-89394
Code English
HYDRALAZINE HYDROCHLORIDE COMPONENT OF BIDIL
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C270
Created by admin on Fri Jun 25 21:00:13 UTC 2021 , Edited by admin on Fri Jun 25 21:00:13 UTC 2021
Code System Code Type Description
WHO INTERNATIONAL PHARMACOPEIA
HYDRALAZINE HYDROCHLORIDE
Created by admin on Fri Jun 25 21:00:13 UTC 2021 , Edited by admin on Fri Jun 25 21:00:13 UTC 2021
PRIMARY Description: A white or almost white, crystalline powder; odourless. Solubility: Soluble in 25 parts of water; slightly soluble in ethanol (~750 g/l) TS; very slightly soluble in ether R. Category: Antihypertensive drug. Storage: Hydralazine hydrochloride should be kept in a well-closed container, protected from light. Additional information: Hydralazine hydrochloride melts at about 275 ?C with decomposition. Even in the absence of light, it is gradually degraded on exposure to a humid atmosphere, the decomposition being faster at higher temperatures. Definition: Hydralazine hydrochloride contains not less than 98.0% and not more than 101.0% of C8H8N4,HCl, calculated with reference to the dried substance.
ChEMBL
CHEMBL276832
Created by admin on Fri Jun 25 21:00:13 UTC 2021 , Edited by admin on Fri Jun 25 21:00:13 UTC 2021
PRIMARY
ECHA (EC/EINECS)
206-151-0
Created by admin on Fri Jun 25 21:00:13 UTC 2021 , Edited by admin on Fri Jun 25 21:00:13 UTC 2021
PRIMARY
RXCUI
82027
Created by admin on Fri Jun 25 21:00:13 UTC 2021 , Edited by admin on Fri Jun 25 21:00:13 UTC 2021
PRIMARY RxNorm
EPA CompTox
304-20-1
Created by admin on Fri Jun 25 21:00:13 UTC 2021 , Edited by admin on Fri Jun 25 21:00:13 UTC 2021
PRIMARY
HSDB
434
Created by admin on Fri Jun 25 21:00:13 UTC 2021 , Edited by admin on Fri Jun 25 21:00:13 UTC 2021
PRIMARY
USP_CATALOG
1313006
Created by admin on Fri Jun 25 21:00:13 UTC 2021 , Edited by admin on Fri Jun 25 21:00:13 UTC 2021
PRIMARY USP-RS
MERCK INDEX
M6072
Created by admin on Fri Jun 25 21:00:13 UTC 2021 , Edited by admin on Fri Jun 25 21:00:13 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C551
Created by admin on Fri Jun 25 21:00:13 UTC 2021 , Edited by admin on Fri Jun 25 21:00:13 UTC 2021
PRIMARY
EVMPD
SUB02553MIG
Created by admin on Fri Jun 25 21:00:13 UTC 2021 , Edited by admin on Fri Jun 25 21:00:13 UTC 2021
PRIMARY
CAS
304-20-1
Created by admin on Fri Jun 25 21:00:13 UTC 2021 , Edited by admin on Fri Jun 25 21:00:13 UTC 2021
PRIMARY
FDA UNII
FD171B778Y
Created by admin on Fri Jun 25 21:00:13 UTC 2021 , Edited by admin on Fri Jun 25 21:00:13 UTC 2021
PRIMARY
PUBCHEM
9351
Created by admin on Fri Jun 25 21:00:13 UTC 2021 , Edited by admin on Fri Jun 25 21:00:13 UTC 2021
PRIMARY
DRUG BANK
DBSALT000792
Created by admin on Fri Jun 25 21:00:13 UTC 2021 , Edited by admin on Fri Jun 25 21:00:13 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY